Focused On-demand Library for Dual specificity protein phosphatase CDC14C

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

A4D256

UPID:

CC14C_HUMAN

Alternative names:

CDC14 cell division cycle 14 homolog C

Alternative UPACC:

A4D256; Q2VIP7; Q6NUS3; Q8NCT2

Background:

Dual specificity protein phosphatase CDC14C, also known as CDC14 cell division cycle 14 homolog C, plays a pivotal role in cellular processes by dephosphorylating proteins modified by proline-directed kinases. This enzyme's unique ability to target dual-specificity substrates underscores its importance in the regulation of cell cycle and signal transduction pathways.

Therapeutic significance:

Understanding the role of Dual specificity protein phosphatase CDC14C could open doors to potential therapeutic strategies. Its critical function in cell cycle regulation and signal transduction pathways presents a promising avenue for drug discovery, aiming to target diseases where these pathways are dysregulated.